
Sandro Ardizzone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2353909/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 11, 649-670.	0.6	1,324
2	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. Journal of Crohn's and Colitis, 2017, 11, 135-149.	0.6	558
3	Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. Journal of Crohn's and Colitis, 2013, 7, 556-585.	0.6	541
4	Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut, 2006, 55, 47-53.	6.1	446
5	Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn's Disease. New England Journal of Medicine, 2015, 372, 1104-1113.	13.9	366
6	Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensus. Endoscopy, 2009, 41, 618-637.	1.0	319
7	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 30-35.	2.4	316
8	Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease. Journal of Crohn's and Colitis, 2011, 5, 477-483.	0.6	310
9	Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology, 2004, 127, 730-740.	0.6	285
10	Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2012, 47, 770-790.	1.3	256
11	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology, 2016, 150, 1568-1578.	0.6	251
12	Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2011, 9, 483-489.e3.	2.4	242
13	Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease. JAMA - Journal of the American Medical Association, 2008, 299, 1690.	3.8	236
14	Biologic Therapy for Inflammatory Bowel Disease. Drugs, 2005, 65, 2253-2286.	4.9	235
15	Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis. American Journal of Gastroenterology, 2009, 104, 2089-2096.	0.2	223
16	Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology, 1995, 108, 345-349.	0.6	197
17	Contrast Radiology, Computed Tomography and Ultrasonography in Detecting Internal Fistulas and Intra-Abdominal Abscesses in Crohn's Disease: A Prospective Comparative Study. American Journal of Gastroenterology, 2003, 98, 1545-1555.	0.2	181
18	Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis, Journal of Internal Medicine, 2000, 247, 63-70	2.7	173

#	Article	IF	CITATIONS
19	Extraintestinal manifestations of inflammatory bowel disease. Digestive and Liver Disease, 2008, 40, S253-S259.	0.4	171
20	Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmunity Reviews, 2013, 12, 703-708.	2.5	167
21	Inflammatory bowel disease: new insights into pathogenesis and treatment. Journal of Internal Medicine, 2002, 252, 475-496.	2.7	153
22	Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Alimentary Pharmacology and Therapeutics, 2011, 34, 724-734.	1.9	146
23	Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut, 2008, 57, 211-217.	6.1	142
24	Sonographic Prevalence of Liver Steatosis and Biliary Tract Stones in Patients with Inflammatory Bowel Disease: Study of 511 Subjects at a Single Center. Journal of Clinical Gastroenterology, 2003, 36, 417-420.	1.1	140
25	Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-A treatment. Haematologica, 2010, 95, 199-205.	1.7	140
26	Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2015, 314, 2524.	3.8	136
27	Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Digestive and Liver Disease, 2003, 35, 619-627.	0.4	130
28	Prevalence of Anemia in Inflammatory Bowel Diseases in European Countries. Inflammatory Bowel Diseases, 2014, 20, 936-945.	0.9	129
29	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Diseasea~†. Digestive and Liver Disease, 2011, 43, 1-20.	0.4	125
30	Variants of CARD15 are Associated with an Aggressive Clinical Course of Crohn's Disease-An IG-IBD Study. American Journal of Gastroenterology, 2005, 100, 84-92.	0.2	116
31	The PROSIT-BIO Cohort. Inflammatory Bowel Diseases, 2017, 23, 233-243.	0.9	116
32	Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal. American Journal of Gastroenterology, 2009, 104, 2760-2767.	0.2	114
33	Small bowel stenosis in Crohn's disease: clinical, biochemical and ultrasonographic evaluation of histological features. Alimentary Pharmacology and Therapeutics, 2003, 18, 749-756.	1.9	111
34	Are Colonoscopy and Bowel Ultrasound Useful for Assessing Response to Short-Term Therapy and Predicting Disease Outcome of Moderate-to-Severe Forms of Ulcerative Colitis?: A Prospective Study. American Journal of Gastroenterology, 2010, 105, 1150-1157.	0.2	110
35	Colorectal cancer in inflammatory bowel disease: Results of the 3rd ECCO pathogenesis scientific workshop (I). Journal of Crohn's and Colitis, 2014, 8, 5-18.	0.6	110
36	Incidence and risk factors for gallstones in patients with inflammatory bowel disease: A large case-control study. Hepatology, 2007, 45, 1267-1274.	3.6	108

#	Article	IF	CITATIONS
37	Endoscopic Palliation in Patients With Incurable Malignant Colorectal Obstruction by Means of Self-expanding Metal Stent. Archives of Surgery, 2011, 146, 1157.	2.3	104
38	Perianal Fistulae Following Infliximab Treatment. Inflammatory Bowel Diseases, 2004, 10, 91-96.	0.9	102
39	Azathioprine in Steroid-Resistant and Steroid-Dependent Ulcerative Colitis. Journal of Clinical Gastroenterology, 1997, 25, 330-333.	1.1	102
40	Pre-illness changes in dietary habits and diet as a risk factor for inflammatory bowel disease: A case-control study. World Journal of Gastroenterology, 2010, 16, 4297.	1.4	92
41	Ultrasonography in the Evaluation of Extension, Activity, and Follow-up of Ulcerative Colitis. Scandinavian Journal of Gastroenterology, 1999, 34, 1103-1107.	0.6	90
42	Transperineal Ultrasound in the Detection of Perianal and Rectovaginal Fistulae in Crohn's Disease. American Journal of Gastroenterology, 2007, 102, 2214-2219.	0.2	90
43	Biologic targeting in the treatment of inflammatory bowel diseases. Biologics: Targets and Therapy, 2009, 3, 77-97.	3.0	88
44	Sympathetic overactivity in active ulcerative colitis: effects of clonidine. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R224-R232.	0.9	83
45	The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis. Fibrogenesis and Tissue Repair, 2013, 6, 13.	3.4	82
46	Small Bowel Adenocarcinomas Complicating Crohn's Disease Are Associated With Dysplasia. Inflammatory Bowel Diseases, 2014, 20, 1584-1592.	0.9	75
47	ls maintenance therapy always necessary for patients with ulcerative colitis in remission?. Alimentary Pharmacology and Therapeutics, 1999, 13, 373-379.	1.9	73
48	Adalimumab in active ulcerative colitis: A "real-life―observational study. Digestive and Liver Disease, 2013, 45, 738-743.	0.4	72
49	An Analysis of the Factors Associated With the Development of Complications in Patients Undergoing Precut Sphincterotomy: A Prospective, Controlled, Randomized, Multicenter Study. American Journal of Gastroenterology, 2009, 104, 2412-2417.	0.2	70
50	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 399-406.	3.7	70
51	Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Digestive and Liver Disease, 2005, 37, 418-423.	0.4	69
52	Replication of interleukin 23 receptor and autophagyrelated 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy. World Journal of Gastroenterology, 2008, 14, 4643.	1.4	66
53	Prevalence and clinical significance of sonographic evidence of mesenteric fat alterations in Crohn's disease. Inflammatory Bowel Diseases, 2008, 14, 1555-1561.	0.9	65
54	Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointestinal Endoscopy, 2007, 65, 982-987.	0.5	64

#	Article	IF	CITATIONS
55	Patients with atherosclerosis may have increased circulating levels of 27â€hydroxycholesterol and cholestenoic acid. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 365-376.	0.6	63
56	A prospective, longitudinal study of nonconventional strictureplasty in Crohn's disease1 1No competing interests declared Journal of the American College of Surgeons, 2004, 199, 8-20.	0.2	62
57	Rheumatic manifestations in inflammatory bowel disease. Autoimmunity Reviews, 2014, 13, 20-23.	2.5	61
58	Infliximab-induced lupus in Crohn's disease: a case report. Digestive and Liver Disease, 2003, 35, 814-817.	0.4	58
59	Use of double-balloon enteroscopy in the management of patients with Crohn's disease: feasibility and diagnostic yield in a high-volume centre for inflammatory bowel disease. Surgical Endoscopy and Other Interventional Techniques, 2009, 23, 2790-2795.	1.3	58
60	A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Alimentary Pharmacology and Therapeutics, 1999, 13, 381-388.	1.9	57
61	Effectiveness and Safety of Vedolizumab in Anti-TNF-NaÃ⁻ve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. Inflammatory Bowel Diseases, 2018, 24, 2442-2451.	0.9	56
62	Review article: the management of steroid dependency in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2007, 26, 779-794.	1.9	55
63	Transperineal Perineal Ultrasound Versus Magnetic Resonance Imaging In the Assessment of Perianal Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 2737-2743.	0.9	55
64	Bowel Ultrasound and Mucosal Healing in Ulcerative Colitis. Digestive Diseases, 2009, 27, 285-290.	0.8	53
65	Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Digestive and Liver Disease, 2011, 43, 946-952.	0.4	53
66	Prospective Study of Long-Term Results and Prognostic Factors After Conservative Surgery for Small Bowel Crohn's Disease. Clinical Gastroenterology and Hepatology, 2009, 7, 183-191.	2.4	52
67	Prevalence of Pancreatic Insufficiency in Inflammatory Bowel Diseases. Assessment by Fecal Elastase-1. Digestive Diseases and Sciences, 2008, 53, 262-270.	1.1	51
68	Small Bowel Carcinomas in Coeliac or Crohn's Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer Italian Consortium. Journal of Crohn's and Colitis, 2017, 11, 942-953.	0.6	51
69	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases, 2019, 25, 568-579.	0.9	51
70	HLA and Autoimmune Digestive Disease: A Clinically Oriented Review for Gastroenterologists. American Journal of Gastroenterology, 2009, 104, 195-217.	0.2	48
71	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Digestive and Liver Disease, 2017, 49, 604-617.	0.4	47
72	Adalimumab for the treatment of Crohn's disease. Biologics: Targets and Therapy, 2008, 2, 763.	3.0	43

#	Article	IF	CITATIONS
73	Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. Journal of Crohn's and Colitis, 2018, 12, 476-488.	0.6	43
74	A Practical Guide to the Management of Distal Ulcerative Colitis. Drugs, 1998, 55, 519-542.	4.9	42
75	Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Alimentary Pharmacology and Therapeutics, 2005, 22, 209-215.	1.9	42
76	Internet use among inflammatory bowel disease patients: an Italian multicenter survey. European Journal of Gastroenterology and Hepatology, 2009, 21, 1036-1041.	0.8	42
77	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2017, 49, 338-358.	0.4	42
78	Validation of the Italian translation of the Inflammatory Bowel Disease Questionnaire. Digestive and Liver Disease, 2011, 43, 535-541.	0.4	41
79	Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study. Inflammatory Bowel Diseases, 2011, 17, 758-766.	0.9	41
80	Peripheral regulatory T cells and serum transforming growth factor-β: Relationship with clinical response to infliximab in Crohn's disease. Inflammatory Bowel Diseases, 2010, 16, 1891-1897.	0.9	40
81	Infliximab in treatment of Crohn's disease: the Milan experience. Digestive and Liver Disease, 2002, 34, 411-418.	0.4	39
82	Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 516-523.	0.9	38
83	Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Digestive and Liver Disease, 2002, 34, 787-793.	0.4	37
84	Anorectal ultrasound for neoplastic and inflammatory lesions. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 113-135.	1.0	37
85	CARD15 Gene Variants and Risk of Reoperation in Crohn's Disease Patients. American Journal of Gastroenterology, 2009, 104, 2483-2491.	0.2	37
86	Portal vein thrombosis in inflammatory bowel diseases: A single-center case series. Journal of Crohn's and Colitis, 2012, 6, 362-367.	0.6	37
87	Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease. Therapeutic Advances in Gastroenterology, 2016, 9, 527-532.	1.4	37
88	Perianal Crohn's disease: Overview. Digestive and Liver Disease, 2007, 39, 957-958.	0.4	36
89	Perianal disease is associated with psychiatric co-morbidity in Crohn's disease in remission. International Journal of Colorectal Disease, 2014, 29, 1285-1290.	1.0	36
90	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2019, 51, 632-639.	0.4	36

6

#	Article	IF	CITATIONS
91	Biologic targeting in the treatment of inflammatory bowel diseases. Biologics: Targets and Therapy, 2009, , 77.	3.0	35
92	Vitamin D and Inflammatory Bowel Disease. Vitamins and Hormones, 2011, 86, 367-377.	0.7	35
93	Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World Journal of Gastroenterology, 2014, 20, 3507.	1.4	35
94	Impact of patient characteristics on the clinical efficacy of mongersen (GEDâ€0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 717-724.	1.9	35
95	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study― Digestive and Liver Disease, 2017, 49, 17-23.	0.4	35
96	The impact of covid-19 pandemic on urgent endoscopy in Italy: a nation-wide multicenter study. Scandinavian Journal of Gastroenterology, 2020, 55, 870-876.	0.6	35
97	Monocyte-derived dendritic cells from Crohn patients show differential NOD2/CARD15-dependent immune responses to bacteria. Inflammatory Bowel Diseases, 2008, 14, 812-818.	0.9	34
98	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Digestive and Liver Disease, 2016, 48, 360-370.	0.4	34
99	Comparative Tolerability of Therapies for Ulcerative Colitis. Drug Safety, 2002, 25, 561-582.	1.4	32
100	Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Digestive and Liver Disease, 2005, 37, 407-417.	0.4	32
101	ABO histo-blood group might modulate predisposition to Crohn's disease and affect disease behavior. Journal of Crohn's and Colitis, 2014, 8, 489-494.	0.6	32
102	Colon Cleansing for Colonoscopy in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 2137-2144.	0.9	32
103	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Autoimmunity Reviews, 2020, 19, 102574.	2.5	32
104	Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study. Digestive and Liver Disease, 2004, 36, 121-124.	0.4	31
105	Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2005, 22, 453-461.	1.9	31
106	Role of the advanced glycation end products receptor in Crohn's disease inflammation. World Journal of Gastroenterology, 2013, 19, 8269.	1.4	31
107	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. Journal of Crohn's and Colitis, 2016, 10, 913-924.	0.6	30
108	Comprehensive review on EUS-guided biliary drainage. World Journal of Gastrointestinal Endoscopy, 2019, 11, 354-364.	0.4	30

#	Article	IF	CITATIONS
109	Randomised clinical trial: the efficacy and safety of propionyl-l-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Alimentary Pharmacology and Therapeutics, 2011, 34, 1088-1097.	1.9	29
110	Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment. Thrombosis and Haemostasis, 2016, 116, 486-495.	1.8	29
111	How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Frontiers in Immunology, 2021, 12, 656362.	2.2	29
112	Imaging of perianal Crohn's disease. Digestive and Liver Disease, 2007, 39, 970-978.	0.4	28
113	Crohn's Disease Loci Are Common Targets of Protozoa-Driven Selection. Molecular Biology and Evolution, 2013, 30, 1077-1087.	3.5	28
114	Immunity, autoimmunity and inflammatory bowel disease. Autoimmunity Reviews, 2014, 13, 1-2.	2.5	28
115	Inflammatory bowel disease approaching the 3rd millennium pathogenesis and therapeutic implications?. European Journal of Gastroenterology and Hepatology, 1999, 11, 27-32.	0.8	27
116	Review: Immunomodulators for all patients with inflammatory bowel disease?. Therapeutic Advances in Gastroenterology, 2010, 3, 31-42.	1.4	27
117	The frame-shift mutation of the NOD2/CARD15 gene is significantly increased in ulcerative colitis: An â^—IG-IBD study. Gastroenterology, 2004, 126, 625-627.	0.6	26
118	Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis. European Journal of Gastroenterology and Hepatology, 2014, 26, 1146-1151.	0.8	26
119	An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. Journal of Clinical Medicine, 2022, 11, 2302.	1.0	25
120	New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. European Journal of Clinical Pharmacology, 2007, 63, 875-878.	0.8	24
121	Serum protein profiling of early and advanced stage Crohn's disease. EuPA Open Proteomics, 2014, 3, 48-59.	2.5	23
122	Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. Digestive and Liver Disease, 2021, 53, 263-270.	0.4	23
123	Cyclosporin treatment for severe active ulcerative colitis. Lancet, The, 1990, 336, 439.	6.3	22
124	CASE REPORT: Ultrasonographic Detection of Toxic Megacolon in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2004, 49, 138-142.	1.1	22
125	Ustekinumab in the management of Crohn's disease: Expert opinion. Digestive and Liver Disease, 2018, 50, 653-660.	0.4	22
126	Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacological Research, 2020, 161, 105206.	3.1	22

#	Article	IF	CITATIONS
127	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease, 2022, 54, 440-451.	0.4	22
128	IBD care in Europe: A comparative audit of the inpatient management of Crohn's disease and ulcerative colitis using the national UK IBD audit tool. Journal of Crohn's and Colitis, 2009, 3, 291-301.	0.6	20
129	An Evolutionary Analysis of RAC2 Identifies Haplotypes Associated with Human Autoimmune Diseases. Molecular Biology and Evolution, 2011, 28, 3319-3329.	3.5	19
130	Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis. World Journal of Gastroenterology, 2009, 15, 2469.	1.4	19
131	Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. American Journal of Gastroenterology, 1998, 93, 799-803.	0.2	18
132	Appropriateness and diagnostic yield of colonoscopy in the management of patients with ulcerative colitis: A prospective study in an open access endoscopy service. Inflammatory Bowel Diseases, 2008, 14, 1133-1138.	0.9	18
133	Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs, 2012, 17, 449-467.	1.0	18
134	Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. Clinical Gastroenterology and Hepatology, 2022, 20, 2741-2752.e6.	2.4	18
135	Guidelines for the treatment of ulcerative colitis in remission. European Journal of Gastroenterology and Hepatology, 1997, 9, 836-841.	0.8	16
136	Lower incidence of COVIDâ€19 in patients with inflammatory bowel disease treated with nonâ€gut selective biologic therapy. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3050-3055.	1.4	16
137	Totally laparoscopic, multi-stage, restorative proctocolectomy for inflammatory bowel diseases. A prospective study on safety, efficacy and long-term results. Digestive and Liver Disease, 2018, 50, 1283-1291.	0.4	15
138	Ulcerative colitis: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy, 2014, 15, 1659-1670.	0.9	14
139	Noninvasive testing in the management of children with suspected inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2019, 54, 586-591.	0.6	14
140	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease â€~AGED' study. European Journal of Gastroenterology and Hepatology, 2019, 31, 1361-1369.	0.8	14
141	Separation of Low- Versus High-grade Crohn's Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis. Journal of Crohn's and Colitis, 2020, 14, 295-302.	0.6	14
142	Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD. Gut, 2022, 71, 1926-1928.	6.1	14
143	Overview of Biological Therapy in Ulcerative Colitis: Current and Future Directions. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 203-213.	0.5	13
144	Erythroderma and toxic epidermal necrolysis caused by to 5-aminosalacylic acid. Inflammatory Bowel Diseases, 2006, 12, 1007-1008.	0.9	12

#	Article	lF	CITATIONS
145	Sulglycotide in the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Gastroduodenal Mucosal Injury: A Controlled Double-Blind, Double-Dummy, Randomized Endoscopic Study versus Placebo in Rheumatic Patients. Scandinavian Journal of Gastroenterology, 1993, 28, 875-878.	0.6	11
146	Nonbiological therapeutic management of ulcerative colitis. Expert Opinion on Pharmacotherapy, 2018, 19, 1747-1757.	0.9	11
147	The topical treatment of distal ulcerative colitis. European Journal of Gastroenterology and Hepatology, 1996, 8, 599-602.	0.8	10
148	Prognostic relevance and putative histogenetic role of cytokeratin 7 and MUC5AC expression in Crohn's disease-associated small bowel carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 667-678.	1.4	10
149	Salsalate in the Treatment of Rheumatoid Arthritis: A Double-Blind Clinical and Gastroscopic Trial versus Piroxicam. II – Endoscopic Evaluation. Journal of International Medical Research, 1989, 17, 320-323.	0.4	9
150	Association of NOD2/CARD15 mutations on Crohn??s disease phenotype in an Italian population. European Journal of Gastroenterology and Hepatology, 2007, 19, 217-223.	0.8	9
151	Use, effectiveness and tolerability of budesonideâ€MMX in ulcerative colitis: A realâ€life experience. United European Gastroenterology Journal, 2019, 7, 1164-1170.	1.6	9
152	Prevalence and significance of mesentery thickening and lymph nodes enlargement in Crohn's disease. Digestive and Liver Disease, 2022, 54, 490-499.	0.4	9
153	Anti-tumour necrosis factor- $\hat{l}\pm$ antibodies and B cell homeostasis in human inflammatory bowel diseases. International Immunopharmacology, 2018, 54, 329-335.	1.7	8
154	Over-the-catheter precut to gain access to the biliary duct during ERCP rendezvous. Surgical Endoscopy and Other Interventional Techniques, 2008, 22, 2323-2325.	1.3	7
155	PillCam Colon and ulcerative colitis: what do physicians need to know?. Endoscopy, 2013, 45, 325-325.	1.0	7
156	Strictureplasties performed by laparoscopic approach for complicated Crohn's disease. A prospective, observational, cohort study. Digestive and Liver Disease, 2021, 53, 1286-1293.	0.4	7
157	Repeated surgery for recurrent Crohn's disease: does the outcome keep worsening operation after operation? A comparative study of 1224 consecutive procedures. Updates in Surgery, 2022, 74, 73-80.	0.9	7
158	Endoscopic full-thickness resection of a submucosal right colon lesion. Endoscopy, 2016, 48, E376-E377.	1.0	5
159	Ultrasonographic Evaluation of Intestinal Fibrosis and Inflammation in Crohn's Disease. The State of the Art. Frontiers in Pharmacology, 2021, 12, 679924.	1.6	5
160	Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. Core Evidence, 2008, 2, 209-29.	4.7	5
161	The Use of Cimetropii Bromidum as Premedication for Endoscopy of the Upper Gastro-Intestinal Tract: A Double-Blind Controlled Clinical Trial. Journal of International Medical Research, 1985, 13, 332-337.	0.4	4
162	How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis?. Inflammatory Bowel Diseases, 2008, 14, S238-S239.	0.9	4

#	Article	IF	CITATIONS
163	Pneumatosis intestinalis and perforation in Crohn's disease: Worrisome or not?. Journal of Crohn's and Colitis, 2014, 8, 338-339.	0.6	4
164	Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. Therapeutics and Clinical Risk Management, 2021, Volume 17, 285-292.	0.9	4
165	Endoscopic Assessment of Tenoxicam- and Piroxicam-Induced Lesions in Osteoarthritic Patients. Drug Investigation, 1991, 3, 53-56.	0.6	3
166	Peptic ulcer therapy with cimetidine versus tripotassium dicitrato bismuthate in rheumatoid arthritis patients undergoing chronic NSAID treatment. Alimentary Pharmacology and Therapeutics, 1998, 12, 343-347.	1.9	3
167	Azathioprine versus mesalamine in steroid-dependent ulcerative colitis: Long-awaited results?. Gastroenterology, 2006, 130, 607-608.	0.6	3
168	Use of colonoscopy in the management of patients with Crohn's disease: Appropriateness and diagnostic yield. Digestive and Liver Disease, 2009, 41, 653-658.	0.4	3
169	Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. Clinical Gastroenterology and Hepatology, 2021, 19, 2293-2301.e1.	2.4	3
170	Has the Removing of the Mesentery during Ileo-Colic Resection an Impact on Post-Operative Complications and Recurrence in Crohn's Disease? Results from the Resection of the Mesentery Study (Remedy). Journal of Clinical Medicine, 2022, 11, 1961.	1.0	3
171	Azathioprine and 6 Mercaptopurine in postoperative maintenance of Crohn's disease remission: Is no evidence of effect an evidence of no effect?. Gastroenterology, 2005, 128, 246-248.	0.6	2
172	Stem Cell Injection for Complex Refractory Perianal Fistulas in Crohn's Disease: A Single Center Initial Experience. Frontiers in Surgery, 2022, 9, 834870.	0.6	2
173	Gastrointestinal tuberculosis presenting as acute abdomen: a case report. Journal of Surgical Case Reports, 2022, 2022, .	0.2	2
174	Effect of Esaprazole on Gastric Mucosal Potential Difference after Oral Administration of Aspirin (ASA). Journal of International Medical Research, 1986, 14, 321-324.	0.4	1
175	Should azathioprine be withdrawn in patients with Crohn's disease who are in long-term remission?. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 348-349.	1.7	1
176	Sigmoid stricture in a 39-year-old female. Gut, 2007, 56, 1247-1247.	6.1	1
177	Is it possible to modify the clinical course of Crohn's disease?. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 428-429.	1.7	1
178	To Stent or Not to Stent?: Palliative Management of Inoperable Colorectal Cancer. American Journal of Gastroenterology, 2010, 105, 1209.	0.2	1
179	Abdominal Symptoms and Colonic Diverticula in Marfan's Syndrome: A Clinical and Ultrasonographic Case Control Study. Journal of Clinical Medicine, 2020, 9, 3141.	1.0	1
180	Impact of the COVID-19 Outbreak on Anesthesiologist Assistance for Endoscopic Procedures. Clinical Endoscopy, 2022, 55, 49-57.	0.6	1

#	Article	IF	CITATIONS
181	Crohn's Disease: Achieving Patients' Benefits Paris, 27th October 2007. Digestive and Liver Disease Supplements, 2008, 2, 1-2.	0.2	0
182	Conventional drugs: the unmet needs. Digestive and Liver Disease Supplements, 2008, 2, 11-12.	0.2	0
183	Is mucosal healing a predictor of decreased risk of Crohn's disease relapse after withdrawal of 1-year, successful adalimumab?. Digestive and Liver Disease Supplements, 2010, 4, 18-21.	0.2	0
184	Anti-tumour necrosis factor \hat{I}_{\pm} antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease. International Immunopharmacology, 2021, 100, 108081.	1.7	0
185	Pathophysiology and therapeutic management of anemia in gastrointestinal disorders. Expert Review of Gastroenterology and Hepatology, 2022, 16, 625-637.	1.4	0